구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | anti-CD19-CAR vector-transduced T cells (anti-CD19-CAR vector-transduced T cells) Hrain Biotechnology Co., Ltd.·CD19 30 trials |
|---|---|
Overview Program | anti-CD19-CAR vector-transduced T cells |
Overview Company | Hrain Biotechnology Co., Ltd. |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Case Report: Remission of a patient with complex combination of autoimmune diseases by anti-CD19 CAR-T cell therapy.. CAR-T cell therapy has been proven effective in various autoimmune diseases, with most studies utilizing lentiviral-transduced CAR-T cells. In recent years, retroviral vector-transduced CAR-T cells-characterized by a high positivity rate, stable cell lines, and lower plasmid requir… |
Clinical Safety signal | Case Report: Remission of a patient with complex combination of autoimmune diseases by anti-CD19 CAR-T cell therapy.. CAR-T cell therapy has been proven effective in various autoimmune diseases, with most studies utilizing lentiviral-transduced CAR-T cells. In recent years, retroviral vector-transduced CAR-T cells-characterized by a high positivity rate, stable cell lines, and lower plasmid requir… |
Clinical Selected reported efficacy | ORR 32% |
Clinical Reported ORR | 32% |
Clinical Result source | ClinicalTrials.gov NCT01865617 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT01865617 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | anti-CD19-CAR vector-transduced T cells (anti-CD19-CAR vector-transduced T cells) Hrain Biotechnology Co., Ltd.·CD19 30 trials |
|---|---|
Overview Program | anti-CD19-CAR vector-transduced T cells |
Overview Company | Hrain Biotechnology Co., Ltd. |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Case Report: Remission of a patient with complex combination of autoimmune diseases by anti-CD19 CAR-T cell therapy.. CAR-T cell therapy has been proven effective in various autoimmune diseases, with most studies utilizing lentiviral-transduced CAR-T cells. In recent years, retroviral vector-transduced CAR-T cells-characterized by a high positivity rate, stable cell lines, and lower plasmid requir… |
Clinical Safety signal | Case Report: Remission of a patient with complex combination of autoimmune diseases by anti-CD19 CAR-T cell therapy.. CAR-T cell therapy has been proven effective in various autoimmune diseases, with most studies utilizing lentiviral-transduced CAR-T cells. In recent years, retroviral vector-transduced CAR-T cells-characterized by a high positivity rate, stable cell lines, and lower plasmid requir… |
Clinical Selected reported efficacy | ORR 32% |
Clinical Reported ORR | 32% |
Clinical Result source | ClinicalTrials.gov NCT01865617 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT01865617 |
추천 비교
추천 비교